Title: Severe imatinib-associated muscle edema in patients with chronic myelogenous leukemia and marked leukocytosis
Abstract: Imatinib is a potent competitive inhibitor of the bcr-abl tyrosine kinase of chronic myelogenous leukemia (CML) [1]. Imatinib is the standard front line therapy of this disease. The FDA-approved st...
Publication Year: 2008
Publication Date: 2008-01-01
Language: en
Type: letter
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 5
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot